DOI: 10.1177/106002809502901013. Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic

Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic

10.1177/106002809502901013

Crossref journal-article

SAGE Publications

Annals of Pharmacotherapy (179)

Abstract

Objective: To review the current knowledge on RP 59500 (quinupristin/dalfopristin, Synercid), a new streptogramin antibiotic, with respect to its pharmacology, pharmacokinetics, pharmacodynamics, mechanism of resistance, and in vitro inhibitory and bactericidal activity. Data Sources: A MEDLINE search using the keywords RP 59500, pristinamycin, virginiamycin, and streptogramin was performed. Relevant abstracts presented at recent scientific conferences also were consulted. Study Selection: Because RP 59500 is a relatively new investigational agent, relevant in vitro and animal studies were selected. All available human studies were included as well. Data Extraction: Data from in vitro and in vivo studies were included, with particular emphasis on human studies. Data Synthesis: RP 59500 is a new injectable streptogramin antibiotic consisting of a mixture of 2 synergistic pristinamycin compounds. RP 59500 possesses in vitro inhibitory and bactericidal activity against most isolates of gram-positive organisms including vancomycin-resistant Enterococcus faecium, selected gram-negative bacteria, and most anaerobic organisms. Based on preliminary data, the drug appears to be metabolized rapidly and extensively while exhibiting a significant postantibiotic effect. Data from ongoing clinical trials suggest that RP 59500 is well-tolerated except for mild injection site irritations. However, before the role of RP 59500 within the vast armamentarium of antimicrobials can be elucidated, additional studies need to be conducted to document its clinical efficacy. Conclusions: Based on in vitro susceptibility testing, in vivo studies, and preliminary clinical data, RP 59500 may be an alternative to the glycopeptides, especially for inherently resistant organisms. Further studies are needed to confirm this agent's in vitro activity and to establish its clinical efficacy.

Bibliography

Chant, C., & Rybak, M. J. (1995). Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic. Annals of Pharmacotherapy, 29(10), 1022â1027.

Authors 2

Clarence Chant (first)
Michael J Rybak (additional)

References 30 Referenced 42

10.1093/jac/30.suppl_A.1
10.1093/jac/16.suppl_A.13 / J Antimicrob Chemother by Le Goffic F. (1985)
10.1093/jac/30.suppl_A.9
10.1093/jac/30.suppl_A.25
10.1093/jac/30.suppl_A.83
10.1093/jac/30.suppl_A.95
10.1128/AAC.35.3.553
10.1093/jac/30.suppl_A.29
10.1128/AAC.37.3.598
10.1093/jac/30.suppl_A.77
SpanglerSK, JacobsMR, AppelbaumPC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, Sparfloxacin, temafloxacin, WIN 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:856-9. (10.1128/AAC.36.4.856)
10.1093/jac/30.suppl_A.39
10.1093/jac/30.suppl_A.45
{'journal-title': 'Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy', 'year': '1993', 'author': 'Casewell MW', 'key': 'bibr14-106002809502901013'} / Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy by Casewell MW (1993)
10.1093/jac/30.1.27
{'journal-title': 'Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy', 'year': '1994', 'author': 'Mahayni R', 'key': 'bibr16-106002809502901013'} / Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy by Mahayni R (1994)
10.1093/jac/30.suppl_A.59
10.1128/AAC.35.7.1267
10.1128/AAC.35.7.1273
10.1093/jac/30.suppl_A.67
10.1093/jac/30.suppl_A.123
{'journal-title': 'Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy', 'year': '1992', 'author': 'Gaillard C', 'key': 'bibr22-106002809502901013'} / Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy by Gaillard C (1992)
10.1093/jac/30.suppl_A.101
Investigator brochure. Synercid (quinupristin/dalfopristin). Rhône-Poulenc Rorer, Collegeville, PA. June, 1994.
10.1093/jac/30.suppl_A.107
10.1093/jac/30.suppl_A.117
10.1128/AAC.36.10.2211
10.1128/AAC.38.3.432
10.1128/AAC.39.7.1505
{'volume-title': 'Presented at the Bacterial Multidrug Resistance Meeting: Overcoming the Multidrug Resistance Challenge', 'year': '1995', 'author': 'Cerwinka S', 'key': 'bibr30-106002809502901013'} / Presented at the Bacterial Multidrug Resistance Meeting: Overcoming the Multidrug Resistance Challenge by Cerwinka S (1995)

Dates

Type	When
Created	8 years, 1 month ago (July 7, 2017, 1:27 a.m.)
Deposited	6 months ago (March 2, 2025, 8:19 p.m.)
Indexed	4 weeks ago (Aug. 7, 2025, 4:23 p.m.)
Issued	29 years, 11 months ago (Oct. 1, 1995)
Published	29 years, 11 months ago (Oct. 1, 1995)
Published Online	29 years, 11 months ago (Oct. 1, 1995)
Published Print	29 years, 11 months ago (Oct. 1, 1995)

Funders 0

None

BibTeX

@article{Chant_1995, title={Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic}, volume={29}, ISSN={1542-6270}, url={http://dx.doi.org/10.1177/106002809502901013}, DOI={10.1177/106002809502901013}, number={10}, journal={Annals of Pharmacotherapy}, publisher={SAGE Publications}, author={Chant, Clarence and Rybak, Michael J}, year={1995}, month=oct, pages={1022–1027} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        7
      ]
    ],
    "date-time": "2025-08-07T20:23:05Z",
    "timestamp": 1754598185323,
    "version": "3.38.0"
  },
  "reference-count": 30,
  "publisher": "SAGE Publications",
  "issue": "10",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            1995,
            10,
            1
          ]
        ],
        "date-time": "1995-10-01T00:00:00Z",
        "timestamp": 812505600000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://journals.sagepub.com/page/policies/text-and-data-mining-license"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        1995,
        10
      ]
    ]
  },
  "abstract": "<jats:sec><jats:title>Objective:</jats:title><jats:p> To review the current knowledge on RP 59500 (quinupristin/dalfopristin, Synercid), a new streptogramin antibiotic, with respect to its pharmacology, pharmacokinetics, pharmacodynamics, mechanism of resistance, and in vitro inhibitory and bactericidal activity. </jats:p></jats:sec><jats:sec><jats:title>Data Sources:</jats:title><jats:p> A MEDLINE search using the keywords RP 59500, pristinamycin, virginiamycin, and streptogramin was performed. Relevant abstracts presented at recent scientific conferences also were consulted. </jats:p></jats:sec><jats:sec><jats:title>Study Selection:</jats:title><jats:p> Because RP 59500 is a relatively new investigational agent, relevant in vitro and animal studies were selected. All available human studies were included as well. </jats:p></jats:sec><jats:sec><jats:title>Data Extraction:</jats:title><jats:p> Data from in vitro and in vivo studies were included, with particular emphasis on human studies. </jats:p></jats:sec><jats:sec><jats:title>Data Synthesis:</jats:title><jats:p> RP 59500 is a new injectable streptogramin antibiotic consisting of a mixture of 2 synergistic pristinamycin compounds. RP 59500 possesses in vitro inhibitory and bactericidal activity against most isolates of gram-positive organisms including vancomycin-resistant Enterococcus faecium, selected gram-negative bacteria, and most anaerobic organisms. Based on preliminary data, the drug appears to be metabolized rapidly and extensively while exhibiting a significant postantibiotic effect. Data from ongoing clinical trials suggest that RP 59500 is well-tolerated except for mild injection site irritations. However, before the role of RP 59500 within the vast armamentarium of antimicrobials can be elucidated, additional studies need to be conducted to document its clinical efficacy. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> Based on in vitro susceptibility testing, in vivo studies, and preliminary clinical data, RP 59500 may be an alternative to the glycopeptides, especially for inherently resistant organisms. Further studies are needed to confirm this agent's in vitro activity and to establish its clinical efficacy. </jats:p></jats:sec>",
  "DOI": "10.1177/106002809502901013",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2017,
        7,
        7
      ]
    ],
    "date-time": "2017-07-07T05:27:27Z",
    "timestamp": 1499405247000
  },
  "page": "1022-1027",
  "source": "Crossref",
  "is-referenced-by-count": 42,
  "title": "Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic",
  "prefix": "10.1177",
  "volume": "29",
  "author": [
    {
      "given": "Clarence",
      "family": "Chant",
      "sequence": "first",
      "affiliation": [
        {
          "name": "Department of Pharmacy, Henry Ford Hospital, Detroit, MI"
        }
      ]
    },
    {
      "given": "Michael J",
      "family": "Rybak",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI; and Director, The Antiinfective Research Laboratory, Department of Pharmacy, Detroit Receiving Hospital, 4201 St Antoini Blvd, Detroit, MI 48201"
        }
      ]
    }
  ],
  "member": "179",
  "published-online": {
    "date-parts": [
      [
        1995,
        10,
        1
      ]
    ]
  },
  "reference": [
    {
      "key": "bibr1-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.1"
    },
    {
      "key": "bibr2-106002809502901013",
      "doi-asserted-by": "crossref",
      "first-page": "13",
      "DOI": "10.1093/jac/16.suppl_A.13",
      "volume": "16",
      "author": "Le Goffic F.",
      "year": "1985",
      "journal-title": "J Antimicrob Chemother"
    },
    {
      "key": "bibr3-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.9"
    },
    {
      "key": "bibr4-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.25"
    },
    {
      "key": "bibr5-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.83"
    },
    {
      "key": "bibr6-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.95"
    },
    {
      "key": "bibr7-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.35.3.553"
    },
    {
      "key": "bibr8-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.29"
    },
    {
      "key": "bibr9-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.37.3.598"
    },
    {
      "key": "bibr10-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.77"
    },
    {
      "key": "bibr11-106002809502901013",
      "doi-asserted-by": "crossref",
      "unstructured": "SpanglerSK, JacobsMR, AppelbaumPC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, Sparfloxacin, temafloxacin, WIN 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:856-9.",
      "DOI": "10.1128/AAC.36.4.856"
    },
    {
      "key": "bibr12-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.39"
    },
    {
      "key": "bibr13-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.45"
    },
    {
      "journal-title": "Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "year": "1993",
      "author": "Casewell MW",
      "key": "bibr14-106002809502901013"
    },
    {
      "key": "bibr15-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.1.27"
    },
    {
      "journal-title": "Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "year": "1994",
      "author": "Mahayni R",
      "key": "bibr16-106002809502901013"
    },
    {
      "key": "bibr17-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.59"
    },
    {
      "key": "bibr18-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.35.7.1267"
    },
    {
      "key": "bibr19-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.35.7.1273"
    },
    {
      "key": "bibr20-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.67"
    },
    {
      "key": "bibr21-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.123"
    },
    {
      "journal-title": "Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy",
      "year": "1992",
      "author": "Gaillard C",
      "key": "bibr22-106002809502901013"
    },
    {
      "key": "bibr23-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.101"
    },
    {
      "key": "bibr24-106002809502901013",
      "unstructured": "Investigator brochure. Synercid (quinupristin/dalfopristin). Rh\u00f4ne-Poulenc Rorer, Collegeville, PA. June, 1994."
    },
    {
      "key": "bibr25-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.107"
    },
    {
      "key": "bibr26-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1093/jac/30.suppl_A.117"
    },
    {
      "key": "bibr27-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.36.10.2211"
    },
    {
      "key": "bibr28-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.38.3.432"
    },
    {
      "key": "bibr29-106002809502901013",
      "doi-asserted-by": "publisher",
      "DOI": "10.1128/AAC.39.7.1505"
    },
    {
      "volume-title": "Presented at the Bacterial Multidrug Resistance Meeting: Overcoming the Multidrug Resistance Challenge",
      "year": "1995",
      "author": "Cerwinka S",
      "key": "bibr30-106002809502901013"
    }
  ],
  "container-title": "Annals of Pharmacotherapy",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://journals.sagepub.com/doi/pdf/10.1177/106002809502901013",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://journals.sagepub.com/doi/pdf/10.1177/106002809502901013",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2025,
        3,
        3
      ]
    ],
    "date-time": "2025-03-03T01:19:08Z",
    "timestamp": 1740964748000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://journals.sagepub.com/doi/10.1177/106002809502901013"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        1995,
        10
      ]
    ]
  },
  "references-count": 30,
  "journal-issue": {
    "issue": "10",
    "published-print": {
      "date-parts": [
        [
          1995,
          10
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1177/106002809502901013"
  ],
  "URL": "http://dx.doi.org/10.1177/106002809502901013",
  "relation": {},
  "ISSN": [
    "1060-0280",
    "1542-6270"
  ],
  "subject": [],
  "container-title-short": "Ann Pharmacother",
  "published": {
    "date-parts": [
      [
        1995,
        10
      ]
    ]
  }
}